Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Abstract

Background Inhibition of MEK stops cell proliferation and induces apoptosis; therefore, this enzyme is a key anticancer target. Trametinib is a selective, orally administered MEK1/MEK2 inhibitor. We aimed to define the maximum tolerated dose and recommended phase 2 dose of trametinib and to assess its safety, pharmacokinetics, pharmacodynamics, and response rate in individuals with advanced solid tumours. Methods We undertook a multicentre phase 1 study in patients with advanced solid tumours and adequate organ function. The study was in three parts: dose escalation to define the maximum tolerated dose; identification of the recommended phase 2 dose; and assessment of pharmacodynamic changes. Intermittent and continuous dosing regimens were analysed. Blood samples and tumour biopsy specimens were taken to assess pharmacokinetic and pharmacodynamic changes. Adverse events were defined with common toxicity criteria, and tumour response was measured by Response Evaluation Criteria In Solid Tumors. This study is registered with ClinicalTrials.gov, number NCT00687622. Findings We enrolled 206 patients (median age 58·5 years, range 19-92). Dose-limiting toxic effects included rash (n=2), diarrhoea (n=1), and central serous retinopathy (n=2). The most common treatment-related adverse events were rash or dermatitis acneiform (n=165; 80%) and diarrhoea (87; 42%), most of which were grade 1 and 2. The maximum tolerated dose was 3 mg once daily and the recommended phase 2 dose was 2 mg…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(12)70270-x

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

See all 559

Metadata

Authors
Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., Peddareddigari, V. G., Le, N. T., Hart, L., Bendell, J. C., Eckhardt, G., Kurzrock, R., Flaherty, K., Burris, H. A., & Messersmith, W. A.
Affiliations
  • Sarah Cannon (US)
  • Abramson Cancer Center (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • University of Colorado Cancer Center (US)
  • Pinnacle Oncology Hematology (US)
  • GlaxoSmithKline (United States) (US)
Corresponding author
Infante, Jeffrey R
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2012-08
Volume
13
Issue
8
Pages
773-781
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2100738068
Cited by
552
References
23
Citations by year
2026: 12 · 2025: 31 · 2024: 26 · 2023: 44 · 2022: 48 · 2021: 31 · 2020: 37 · 2019: 37 · 2018: 36 · 2017: 37 · 2016: 63 · 2015: 49 · 2014: 50 · 2013: 45 · 2012: 5
FWCI
19.17
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
GlaxoSmithKline
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
trametinib, MEK inhibitors, maximum tolerated dose, recommended phase 2 dose, dose-limiting toxicity, acneiform rash, diarrhea, central serous chorioretinopathy, pharmacokinetics, pharmacodynamics, pathway inhibition, advanced solid tumors, oral anticancer drugs, tumor response rate
MeSH terms
Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Biopsy, Drug Administration Schedule, Female, Half-Life, Humans, Male, Metabolic Clearance Rate, Middle Aged, Neoplasms, Pyridones, Pyrimidinones, United States, Treatment Outcome, Drug Monitoring, Area Under Curve, Maximum Tolerated Dose, Protein Kinase Inhibitors, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Young Adult, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. https://app.cochat.ai/papers/10.1016/s1470-2045(12)70270-x
The paper
Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., Peddareddigari, V. G., Le, N. T., Hart, L., Bendell, J. C., Eckhardt, G., Kurzrock, R., Flaherty, K., Burris, H. A., & Messersmith, W. A. (2012). Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(12)70270-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.